Public Trust Tracker Search

INV-069 · Money & ethics · Conflicts of interest

ARPA-H director's menopause-company stock and the hormone-therapy warning change

Stage 2 of 5: Inquiry · Letters and records requests · Last development 12 Nov 2026

Alicia Jackson, director of the Advanced Research Projects Agency for Health (ARPA-H) at HHS, founded Evernow, an online platform for menopause treatment. When HHS announced in November 2025 that it would remove "black box" warnings from hormone replacement therapies, she praised the decision at the press conference while, according to her financial disclosures, holding Evernow stock worth $115,002 to $300,000 plus stock options. Ethics experts told ProPublica that federal law bars officials from participating personally and substantially in matters affecting their own finances. Her two disclosures, filed in October 2025 and August 2026, have not been certified by the agency's ethics office. HHS says she has been placed on administrative leave. On 12 November 2026 the Campaign Legal Center asked the HHS inspector general to investigate.

It is unclear what role, if any, Jackson played in the decision: the FDA regulates drugs, and its expert panel had recommended dropping the warning before she joined the government. Ethics experts' views are not findings; no official body has found a violation. Evernow says she no longer holds a financial interest in the company. Being listed is not a finding of wrongdoing.

People
Alicia Jackson, Evernow
Agencies
HHS (ARPA-H), FDA
Reviewed by
Campaign Legal Center (complaint to the HHS inspector general)

Timeline

  1. (Allegation, Campaign Legal Center) The Campaign Legal Center asks HHS Inspector General T. March Bell to investigate whether Jackson "violated recusal requirements and financial disclosure laws", including by "failing to recuse or obtain a conflicts of interest waiver" before taking part in the removal of the "black box" warning on hormone therapies, and whether she fully disclosed her and her spouse's interests in private investment funds. The complaint cites the criminal conflict-of-interest law (18 U.S.C. 208) and the Ethics in Government Act. [3]

  2. ProPublica reports that Jackson's disclosures list $115,002 to $300,000 in Evernow stock and options, that both disclosures remain uncertified, and that no ethics waiver for her appears in Office of Government Ethics records. HHS says she has been placed on administrative leave and that it will "assess the facts before determining any change in her status." [1]

  3. Asked by Bloomberg Law about a limited conflict-of-interest waiver Jackson had sought, HHS Press Secretary Emily Hilliard says: "Alicia Jackson is currently on administrative leave", without giving a reason. Bloomberg Law reports on a draft HHS memo, obtained through a records request in July, that would grant Jackson a limited waiver under 18 U.S.C. 208(b)(1). The undated, unsigned draft says that since joining in October 2025 she "has been required to recuse from a significant portion of the duties" of the director because of her financial interests, and that without a waiver she is limited to broad policy discussions on "Make America Healthy Again" and artificial intelligence. OGE and HHS records requests by Bloomberg Law produced no evidence of an approved waiver. [5]

  4. (Reported) ARPA-H extends Palantir Technologies' data-infrastructure contract by a year, a renewal worth up to $13.7 million, according to ProPublica and Bloomberg Law. Jackson's disclosures list Palantir stock of $5,000,001 to $25,000,000 in her spouse's account. HHS has not answered whether Jackson recused herself from the Palantir contract. [1]

  5. HHS announces it will remove "black box" warnings from hormone replacement therapies. Jackson speaks at the press conference: "The science is clear: Hormone therapy is safe and effective." [1]

Responses

  • HHS spokesperson (Oct 2026): "HHS requires all officials to comply with federal ethics laws, regulations, and policies." HHS declined to say whether the inspector general is investigating. [1]
  • Evernow (28 Oct 2026): Says Jackson does not currently hold a financial interest in the company. Jackson did not respond to ProPublica. [1]
  • HHS, Jackson and her spouse's fund (13 Nov 2026): Asked by ProPublica about the complaint, none commented. [4]

Who is acting on it

  • Review HHS (internal review): Placed Jackson on administrative leave and said it will "assess the facts before determining any change in her status" (29 Oct 2026, Under way)
  • Asked for an investigation Campaign Legal Center: (Allegation) Asked the HHS inspector general to investigate whether Jackson violated recusal and financial disclosure laws, including by not recusing or obtaining a waiver before the hormone therapy warning decision (12 Nov 2026, No reply or result recorded yet)

Sources

  1. ProPublica, 29 Oct 2026
  2. Bloomberg Law, Oct 2026
  3. Campaign Legal Center, complaint to the HHS inspector general, 12 Nov 2026
  4. ProPublica, 13 Nov 2026
  5. Bloomberg Law, 26 Oct 2026 (updated 29 Oct)
  6. ProPublica, Trump Team Financial Disclosures: Alicia Jackson (OGE 278e reports, Oct 2025 and Aug 2026)

Cite this case

Public Trust Tracker. "ARPA-H director's menopause-company stock and the hormone-therapy warning change" (INV-069). Last updated 12 Nov 2026. https://publictrusttracker.org/case/inv-069-arpa-h-directors-menopause-company-stock-and-the-hormone/

Suggest a fact check